Last updated 2 days ago

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

570 patients around the world
Available in Argentina, Chile, United States, Colombia, Brazil, Spain
Bristol-Myers Squibb
570Patients around the world
This study is for people with
Skin cancer
Melanoma
Requirements for the patient
From 12 Years
All Gender
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy